Bonnie Leung

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 16

Top Topics

Epidermal Growth Factor Receptor

Ejection Fraction

Brain Metastases

Small Cell Lung Cancer

Top Venues

Current oncology (Toronto, Ont.)

Communications medicine

JCO oncology practice

Psycho-oncology

This page only lists publications with an associated author ORCID identifier.

Publications

John-Jose Nunez, Bonnie Leung, Cheryl Ho, Raymond T Ng, Alan T Bates
Predicting which patients with cancer will see a psychiatrist or counsellor from their initial oncology consultation document using natural language processing. Communications medicine 4 (1) (2024)
John-Jose Nunez, Bonnie Leung, Cheryl Ho, Raymond T Ng, Alan T Bates
Predicting which patients with cancer will see a psychiatrist or counsellor from their initial oncology consultation document using natural language processing. Communications medicine 4 (1) (2024)
John-Jose Nunez, Bonnie Leung, Cheryl Ho, Raymond T Ng, Alan T Bates
Predicting which patients with cancer will see a psychiatrist or counsellor from their initial oncology consultation document using natural language processing. Communications medicine 4 (1) (2024)
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Marie-Hélène Denault, Jamie Feng, Shelley Kuang, Aria Shokoohi, Bonnie Leung, Mitchell Liu, Eric Berthelet, Janessa Laskin, Sophie Sun, Tina Zhang, Cheryl Ho, Barbara L Melosky
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression. Current oncology (Toronto, Ont.) 30 (8) (2023)
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Bonnie Leung, Selina K Wong, Cheryl Ho
End-of-Life Health Resource Utilization for Limited English-Proficient Patients With Advanced Non-Small-Cell Lung Cancer. JCO oncology practice 18 (10) (2022)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Lauren Jones, Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing. Current oncology (Toronto, Ont.) 29 (11) (2022)
Bonnie Leung, Janessa Laskin, Jonn Wu, Alan Bates, Cheryl Ho
Assessing the psychosocial needs of newly diagnosed patients with nonsmall cell lung cancer: Identifying factors associated with distress. Psycho-oncology 28 (4) (2019)